P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES. (23rd June 2022) - Tan, S.; Arbelaez, A.; Chee, L.; Fong, C. Y.; Hiwase, D.; Kannourakis, G.; Kwan, J.; Liang, J.; Puliyayil, A.; Rose, H.; Ross, D.; Teh, T.-C.; et al.